This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • World Health  • Statistics and Research Methods  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Xavier Bosch, MD, PhD

JAMA. 2005;294:2014-2015.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

European academic research institutions and pharmaceutical companies have teamed up to encourage the development of treatments for rare diseases. The goal of the European Rare Diseases Therapeutic Initiative (ERDITI): to promote the evaluation of compounds that have been abandoned by drug companies.

Although development of drugs for rare diseases benefits from orphan drug legislation in Europe and the United States, most companies cannot justify the cost of traditional pharmaceutical research, including screening of compounds and preclinical development. "The thousands of compounds that have been developed by pharmaceutical companies for more common diseases but that were abandoned or failed to achieve registration . . . represent a treasure worth exploiting," explained Alain Fischer, MD, of Necker University Hospital in Paris and colleagues in an article recently published online in PLoS Medicine (doi:10.1371/plosmedicine0020243). "The availability of such compounds could allow us to shortcut the traditional route of pharmaceutical development and evaluate swiftly—at . . . [Full Text of this Article]

A COLLABORATIVE CONTRACT



CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?